Dr. Darvy L. Mann, MD
Pediatrics (Pediatrics Physician)
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Texas Medical Branch at Galveston
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
TX license P9092 (first issued 2014; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Associated Clinicians of East Texas (108 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 8 companies reported 18 payments worth $385 in total to this clinician.
| Corium, LLC | $172 |
|---|---|
| Pfizer Inc. | $63.47 |
| Seqirus USA Inc | $41.56 |
| Merck Sharp & Dohme LLC | $31.18 |
| Regeneron Healthcare Solutions, Inc. | $27.27 |
| Genzyme Corporation | $19.06 |
| GlaxoSmithKline, LLC. | $16.47 |
| Collegium Pharmaceutical, Inc. | $13.98 |
| Food and Beverage | $385 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $59,717 in research payments for these studies, mostly to the institutions running them.
- A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.